<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>BUD-Listed — Portfolio on 6ix</title>
<link>https://6ix.com/p/bud-listed</link>
<description>Top companies trading on BUD, ranked by market cap.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 14:47:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/portfolio/bud-listed" rel="self" type="application/rss+xml" />
<item>
<title>Basf Se: Growing Home with BASF 2026 winners announced</title>
<link>https://6ix.com/company/basf-se/news/growing-home-with-basf-2026-winners-announced</link>
<guid isPermaLink="true">https://6ix.com/company/basf-se/news/growing-home-with-basf-2026-winners-announced</guid>
<pubDate>Tue, 28 Apr 2026 14:47:00 GMT</pubDate>
<description>BASF to distribute $160,000 to 12 organizations making an impact in rural Canadian communitiesCALGARY, ALBERTA, April 28, 2026 (GLOBE NEWSWIRE) -- News ReleaseGrowing Home with BASF 2026 winners announced BASF to distribute $160,000 to 12 organizations making an impact in rural Canadian communities CALGARY, ALBERTA, April 28, 2026 – BASF Agricultural Solutions Canada (BASF) is proud to announce the 2026 winners of the Growing Home with BASF program, an annual community-giving program dedicated</description>
</item>
<item>
<title>Bayer Ag Na: AskBio's Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease</title>
<link>https://6ix.com/company/bayer-ag-na/news/askbios-viralgen-to-supply-commercial-scale-drug-product-for-regenerate-pd-investigational-gene-therapy-phase-ii-trial-for-parkinsons-disease</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/askbios-viralgen-to-supply-commercial-scale-drug-product-for-regenerate-pd-investigational-gene-therapy-phase-ii-trial-for-parkinsons-disease</guid>
<pubDate>Mon, 20 Apr 2026 12:00:00 GMT</pubDate>
<description>Berlin, Germany, and Durham, N.C., USA, April 20, 2026 (GLOBE NEWSWIRE) -- Not intended for UK Media Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to deliver high-purity product with greater efficiency AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that it has introduced its proprietary, commercially ready manufacturing process to supply ametefg</description>
</item>
<item>
<title>Bayer Ag Na: Bayer Canada Supports New School of Medicine at Simon Fraser University (SFU) With Full Tuition Entrance Award for Inaugural Class</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-canada-supports-new-school-of-medicine-at-simon-fraser-university-sfu-with-full-tuition-entrance-award-for-inaugural-class</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-canada-supports-new-school-of-medicine-at-simon-fraser-university-sfu-with-full-tuition-entrance-award-for-inaugural-class</guid>
<pubDate>Wed, 15 Apr 2026 20:33:00 GMT</pubDate>
<description>MISSISSAUGA, Ontario, April 15, 2026--Bayer Canada is proud to support the Simon Fraser University (SFU) School of Medicine - the first medical school in Western Canada in nearly 60 years. The new school is dedicated to help improve primary care and the critical shortage of family doctors in British Columbia, where approximately 800,000 residents lack access to a primary care physician.</description>
</item>
<item>
<title>Basf Se: Paine Schwartz Partners Announces Sale of AgBiTech to BASF Agricultural Solutions</title>
<link>https://6ix.com/company/basf-se/news/paine-schwartz-partners-announces-sale-of-agbitech-to-basf-agricultural-solutions</link>
<guid isPermaLink="true">https://6ix.com/company/basf-se/news/paine-schwartz-partners-announces-sale-of-agbitech-to-basf-agricultural-solutions</guid>
<pubDate>Wed, 01 Apr 2026 13:00:00 GMT</pubDate>
<description>Paine Schwartz Partners ("Paine Schwartz"), the largest private equity firm dedicated to sustainable food chain investing, today announced the successful sale of AgBiTech, a global leader in biological crop protection solutions, to BASF Agricultural Solutions, a division of BASF.</description>
</item>
<item>
<title>Bayer Ag Na: AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure</title>
<link>https://6ix.com/company/bayer-ag-na/news/askbio-announces-completion-of-enrollment-in-phase-2-clinical-trial-of-ab-1002-investigational-gene-therapy-for-heart-failure</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/askbio-announces-completion-of-enrollment-in-phase-2-clinical-trial-of-ab-1002-investigational-gene-therapy-for-heart-failure</guid>
<pubDate>Wed, 01 Apr 2026 06:40:00 GMT</pubDate>
<description>Durham, N.C., April 01, 2026 (GLOBE NEWSWIRE) -- Final participant randomized in the GenePHIT Phase 2 clinical trial assessing safety and efficacy of AB-1002 for adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptomsInitial results are expected in the first half of 2027Completion of enrollment marks significant milestone in progression of heart failure clinical program and included the largest number of participants to date to receive AB-10</description>
</item>
<item>
<title>Bayer Ag Na: National Advertising Division Recommends Bayer Modify or Discontinue Certain One A Day Men’s Pre-Conception Health Complete Multivitamin Claims</title>
<link>https://6ix.com/company/bayer-ag-na/news/national-advertising-division-recommends-bayer-modify-or-discontinue-certain-one-a-day-mens-pre-conception-health-complete-multivitamin-claims</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/national-advertising-division-recommends-bayer-modify-or-discontinue-certain-one-a-day-mens-pre-conception-health-complete-multivitamin-claims</guid>
<pubDate>Tue, 31 Mar 2026 15:45:00 GMT</pubDate>
<description>Following a challenge brought by OLLY PBC, BBB National Programs’ National Advertising Division recommended that Bayer HealthCare LLC discontinue or modify certain claims for its One A Day® Men’s Pre-Conception Health Complete Multivitamin, a product marketed for men who are trying to conceive.New York, NY, March 31, 2026 (GLOBE NEWSWIRE) -- Following a challenge brought by OLLY PBC, BBB National Programs’ National Advertising Division recommended that Bayer HealthCare LLC discontinue or modify</description>
</item>
<item>
<title>Bayer Ag Na: Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-announces-leadership-change-within-pharmaceuticals-worldwide-markets-organization-in-the-us-to-support-companys-full-growth-potential-1</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-announces-leadership-change-within-pharmaceuticals-worldwide-markets-organization-in-the-us-to-support-companys-full-growth-potential-1</guid>
<pubDate>Tue, 31 Mar 2026 15:30:00 GMT</pubDate>
<description>BERLIN, March 31, 2026--Bayer today announced a leadership change within its Pharmaceuticals’ Worldwide Markets organization to accelerate the strong performance and growth of its key pharmaceutical products in the U.S.</description>
</item>
<item>
<title>Bayer Ag Na: Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-crop-science-canada-redefines-canola-innovation-with-new-advancing-better-canola-initiative</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-crop-science-canada-redefines-canola-innovation-with-new-advancing-better-canola-initiative</guid>
<pubDate>Thu, 26 Mar 2026 15:30:00 GMT</pubDate>
<description>CALGARY, Alberta, March 26, 2026--Bayer Crop Science Canada launches Advancing Better Canola (ABCs), an industry-wide initiative to challenge and redefine how it thinks about canola innovation in support of Canadian farmers. Throughout 2026, the Bayer ABCs will drive dialogue, collaboration, and advocacy, while integrating genetics, agronomy, crop protection, and digital tools to better understand how to enhance its role in canola.</description>
</item>
<item>
<title>Bayer Ag Na: Bayer Crop Science Launches 2026 Opportunity Scholarship Program</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-crop-science-launches-2026-opportunity-scholarship-program</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-crop-science-launches-2026-opportunity-scholarship-program</guid>
<pubDate>Mon, 16 Mar 2026 15:00:00 GMT</pubDate>
<description>CALGARY, Alberta, March 16, 2026--Bayer Crop Science Canada is excited to support the future of Canadian agriculture with its 2026 Bayer Crop Science Opportunity Scholarship. Through the scholarship, students entering post-secondary education in agriculture, food science or culinary arts are eligible for one of 12 scholarships valued at $5000 (CAD), with preference given to two applicants of Canadian Indigenous heritage.</description>
</item>
<item>
<title>Bayer Ag Na: KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease</title>
<link>https://6ix.com/company/bayer-ag-na/news/kerendiar-finerenone-meets-primary-endpoint-in-investigational-phase-iii-find-ckd-study-in-patients-with-non-diabetic-chronic-kidney-disease</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/kerendiar-finerenone-meets-primary-endpoint-in-investigational-phase-iii-find-ckd-study-in-patients-with-non-diabetic-chronic-kidney-disease</guid>
<pubDate>Mon, 16 Mar 2026 07:30:00 GMT</pubDate>
<description>WHIPPANY, N.J., March 16, 2026--The Phase III study FIND-CKD (NCT05047263) — investigating the efficacy and safety of KERENDIA® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney disease (CKD) — has met its primary endpoint.1 The results demonstrated a statistically significant improvement versus placebo in the primary efficacy outcome of estimated glomerular filtration rate (eGFR) slope, defined as the mean annual rate of change from ba</description>
</item>
<item>
<title>Bayer Ag Na: NurExone Announces Corporate Updates</title>
<link>https://6ix.com/company/bayer-ag-na/news/nurexone-announces-corporate-updates-1</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/nurexone-announces-corporate-updates-1</guid>
<pubDate>Wed, 11 Mar 2026 12:28:00 GMT</pubDate>
<description>Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement ClosingTORONTO and HAIFA, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced several developments supporting its planned growth, increasing awareness in Europe, and</description>
</item>
<item>
<title>Bayer Ag Na: Missouri Court Grants Preliminary Approval of Roundup™ Class Settlement to Resolve Current and Future Claims</title>
<link>https://6ix.com/company/bayer-ag-na/news/missouri-court-grants-preliminary-approval-of-rounduptm-class-settlement-to-resolve-current-and-future-claims</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/missouri-court-grants-preliminary-approval-of-rounduptm-class-settlement-to-resolve-current-and-future-claims</guid>
<pubDate>Wed, 04 Mar 2026 17:37:00 GMT</pubDate>
<description>ST. LOUIS, March 04, 2026--Today, a judge in the Circuit Court of the City of St. Louis, Missouri granted preliminary approval of a class action settlement to resolve current and potential future Roundup claims alleging non-Hodgkin lymphoma (NHL) injuries. The motion was filed by leading plaintiff law firms representing the class.</description>
</item>
<item>
<title>Bayer Ag Na: New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments</title>
<link>https://6ix.com/company/bayer-ag-na/news/new-fda-510k-clearance-expands-bayers-medradr-mrxperion-mr-injection-system-support-across-diverse-range-of-mr-environments-8</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/new-fda-510k-clearance-expands-bayers-medradr-mrxperion-mr-injection-system-support-across-diverse-range-of-mr-environments-8</guid>
<pubDate>Wed, 04 Mar 2026 13:00:00 GMT</pubDate>
<description>WHIPPANY, N.J., March 04, 2026--Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments.</description>
</item>
<item>
<title>Bayer Ag Na: Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-reports-results-for-the-investigational-targeted-radionuclide-therapy-225ac-psma-trillium-in-advanced-metastatic-prostate-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-reports-results-for-the-investigational-targeted-radionuclide-therapy-225ac-psma-trillium-in-advanced-metastatic-prostate-cancer</guid>
<pubDate>Fri, 27 Feb 2026 17:43:00 GMT</pubDate>
<description>BERLIN, February 27, 2026--Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy (TAT) in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). The dose for expansion was successfully identified, with ≥80% of patients achieving a PSA50 response at the expansion dose.</description>
</item>
<item>
<title>Bayer Ag Na: Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayers-xofigor-radium-223-dichloride-plus-enzalutamide-demonstrates-significant-overall-survival-benefit-in-peace-3-trial-in-patients-with-metastatic-castration-resistant-prostate-cancer-with-bone-metastases</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayers-xofigor-radium-223-dichloride-plus-enzalutamide-demonstrates-significant-overall-survival-benefit-in-peace-3-trial-in-patients-with-metastatic-castration-resistant-prostate-cancer-with-bone-metastases</guid>
<pubDate>Thu, 26 Feb 2026 16:28:00 GMT</pubDate>
<description>WHIPPANY, N.J., February 26, 2026--Bayer’s XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases</description>
</item>
<item>
<title>Bayer Ag Na: Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-alleges-jandjs-claims-regarding-nubeqar-are-deeply-flawed-and-intentionally-aimed-at-boosting-sales-of-jandjs-erleada</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-alleges-jandjs-claims-regarding-nubeqar-are-deeply-flawed-and-intentionally-aimed-at-boosting-sales-of-jandjs-erleada</guid>
<pubDate>Mon, 23 Feb 2026 15:28:00 GMT</pubDate>
<description>WHIPPANY, N.J., February 23, 2026--Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA</description>
</item>
<item>
<title>Bayer Ag Na: Bayer, John Deere Further Integrate FieldView and Operations Center to Improve Customer Experience for 2026 Season</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-john-deere-further-integrate-fieldview-and-operations-center-to-improve-customer-experience-for-2026-season-1</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-john-deere-further-integrate-fieldview-and-operations-center-to-improve-customer-experience-for-2026-season-1</guid>
<pubDate>Mon, 23 Feb 2026 15:00:00 GMT</pubDate>
<description>ST. LOUIS, February 23, 2026--Bayer and John Deere today announced a new capability that simplifies how U.S. farmers and advisors move from agronomic decisions to precise execution in the field. Beginning this season, customers can wirelessly transfer FieldView™ prescriptions to create Work Plans in Operations Center™. This eliminates the need for thumb drives and other manual steps that slow down field activities and increase the risk of errors.</description>
</item>
<item>
<title>Bayer Ag Na: Monsanto Announces Roundup™ Class Settlement Agreement to Resolve Current and Future Claims</title>
<link>https://6ix.com/company/bayer-ag-na/news/monsanto-announces-rounduptm-class-settlement-agreement-to-resolve-current-and-future-claims</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/monsanto-announces-rounduptm-class-settlement-agreement-to-resolve-current-and-future-claims</guid>
<pubDate>Tue, 17 Feb 2026 16:50:00 GMT</pubDate>
<description>LEVERKUSEN, Germany & ST. LOUIS, February 17, 2026--Today, Monsanto announced a proposed U.S. nationwide class settlement designed to resolve current and future Roundup™ claims alleging Non-Hodgkin lymphoma (NHL) injuries through a long-term claims program. Leading plaintiff law firms representing the class filed a motion today seeking preliminary approval of the settlement in the Circuit Court of the City of St. Louis, Missouri. The proposed class combined with Supreme Court review in the Durne</description>
</item>
<item>
<title>Bayer Ag Na: Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-aspirin-partners-celebrity-chef-130100163</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-aspirin-partners-celebrity-chef-130100163</guid>
<pubDate>Thu, 12 Feb 2026 13:01:00 GMT</pubDate>
<description>WHIPPANY, N.J., February 12, 2026--This American Heart Month, Bayer® Aspirin continues its mission to help people uncover the heart health risk factors they may not see with the launch of the Heart to Heart Bistro presented by Bayer® Aspirin. Created in partnership with Celebrity Chef, Jeff Mauro, the immersive dark dining experience invites Americans to confront one of the most dangerous and often overlooked barriers to heart health – denial – by bringing the unseen risk factors of cardiovascul</description>
</item>
<item>
<title>Basf Se: Leading Automation Capabilities of XtalPi Recognized by Global Chemical Giant - Successful Launch of Advanced Automated Workstation at BASF</title>
<link>https://6ix.com/company/basf-se/news/leading-automation-capabilities-of-xtalpi-recognized-by-global-chemical-giant-successful-launch-of-advanced-automated-workstation-at-basf</link>
<guid isPermaLink="true">https://6ix.com/company/basf-se/news/leading-automation-capabilities-of-xtalpi-recognized-by-global-chemical-giant-successful-launch-of-advanced-automated-workstation-at-basf</guid>
<pubDate>Mon, 09 Feb 2026 12:14:00 GMT</pubDate>
<description>Chemistry serves as the foundational pillar of material innovation and transformation. It supports and shapes almost every aspect of modern industries. Recently, XtalPi Inc. (2228.HK), a global leader in AI- and robotics driven research and development (R&D) platform, announced the successful deployment of its automated formulation stability testing workstation at BASF, a world-renowned giant in the chemical industry. This collaboration enables BASF to build an end‑to‑end automated system that i</description>
</item>
<item>
<title>Bayer Ag Na: Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-asundexian-demonstrated-substantial-26-171500588</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-asundexian-demonstrated-substantial-26-171500588</guid>
<pubDate>Thu, 05 Feb 2026 17:15:00 GMT</pubDate>
<description>NEW ORLEANS, February 05, 2026--Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor XIa inhibitor asundexian (50mg) compared to placebo, both in combination with antiplatelet therapy. Asundexian significantly reduced ischemic stroke by 26% (csHR 0.74; 95% CI 0.65–0.84; p<.0001), in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase in</description>
</item>
<item>
<title>Basf Se: BASF Agricultural Solutions Canada opens 2026 nominations for Growing Home with BASF</title>
<link>https://6ix.com/company/basf-se/news/basf-agricultural-solutions-canada-opens-2026-nominations-for-growing-home-with-basf</link>
<guid isPermaLink="true">https://6ix.com/company/basf-se/news/basf-agricultural-solutions-canada-opens-2026-nominations-for-growing-home-with-basf</guid>
<pubDate>Tue, 03 Feb 2026 16:00:00 GMT</pubDate>
<description>Canadian farmers are invited to nominate local organizations that make a meaningful difference in their communities for a chance to share in a $160,000 prize fund Growing Home with BASF Growing Home with BASF is an annual community giving program that empowers Canadians to give back to organizations that make a difference in their hometown. CALGARY, ALBERTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- After an outpouring of community engagement in 2025, BASF Agricultural Solutions Canada is inviting Canad</description>
</item>
<item>
<title>Bayer Ag Na: Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-teams-up-with-former-professional-quarterback-tony-romo-on-highlights-real-campaign</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-teams-up-with-former-professional-quarterback-tony-romo-on-highlights-real-campaign</guid>
<pubDate>Thu, 29 Jan 2026 13:30:00 GMT</pubDate>
<description>WHIPPANY, N.J., January 29, 2026--Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign</description>
</item>
<item>
<title>Bayer Ag Na: Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-investing-more-than-dollar45m-cad-to-build-world-class-canola-research-and-development-facility-in-canada</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-investing-more-than-dollar45m-cad-to-build-world-class-canola-research-and-development-facility-in-canada</guid>
<pubDate>Tue, 27 Jan 2026 16:00:00 GMT</pubDate>
<description>CALGARY, Alberta, January 27, 2026--Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada’s leadership in canola innovation by establishing a cutting-edge canola innovation centre. Located in Winnipeg, Manitoba, the facility will house seed development work for canola, camelina and winter canola, focusing on trait integration, yield trial seed processing and seed quality analysis.</description>
</item>
<item>
<title>Bayer Ag Na: Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-present-results-phase-iii-123000389</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-present-results-phase-iii-123000389</guid>
<pubDate>Tue, 27 Jan 2026 12:30:00 GMT</pubDate>
<description>BERLIN, January 27, 2026--Bayer today announced that the main results from its global, landmark Phase III study OCEANIC-STROKE of asundexian in secondary stroke prevention, will be presented during two late-breaking sessions at the upcoming American Stroke Association’s International Stroke Conference (ISC) 2026. The conference will be held February 4-6 in New Orleans, Louisiana, USA.</description>
</item>
<item>
<title>Bayer Ag Na: LEGAL NOTICE TO ALL CANADIANS OUTSIDE OF QUÉBEC - NOTICE OF CLASS ACTION CERTIFICATION AND SETTLEMENT APPROVAL HEARING</title>
<link>https://6ix.com/company/bayer-ag-na/news/legal-notice-to-all-canadians-outside-of-quebec-notice-of-class-action-certification-and-settlement-approval-hearing</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/legal-notice-to-all-canadians-outside-of-quebec-notice-of-class-action-certification-and-settlement-approval-hearing</guid>
<pubDate>Sat, 24 Jan 2026 13:00:00 GMT</pubDate>
<description>A class action, Tluchak (Estate) v Bayer Inc., QBG-RG-00517-2016, commenced in the Court of King's Bench for Saskatchewan, was certified to advance claims relating to the prescription drug Xarelto® that Bayer Inc. and certain affiliates ("Bayer") marketed in Canada. Similar class proceedings were filed elsewhere in Canada, including in Québec. This notice respecting the Saskatchewan class action is targeted to all Canadian residents other than residents of Québec. A separate notice respecting th</description>
</item>
<item>
<title>Bayer Ag Na: Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-vanderbilt-university-medical-center-073000951</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-vanderbilt-university-medical-center-073000951</guid>
<pubDate>Tue, 20 Jan 2026 07:30:00 GMT</pubDate>
<description>BERLIN & NASHVILLE, Tenn., January 20, 2026--Bayer and Vanderbilt University Medical Center (VUMC) today announced that they have entered a strategic five-year collaboration agreement to advance innovative therapies from target identification through Investigational New Drug (IND) application. The agreement spans across all indications currently pursued by Bayer, initially focusing on cardiovascular and kidney diseases, two therapeutic areas with significant unmet medical need.</description>
</item>
<item>
<title>Basf Se: #OurPlasticsJourney: BASF showcases innovative and sustainable solutions at PlastIndia 2026</title>
<link>https://6ix.com/company/basf-se/news/ourplasticsjourney-basf-showcases-innovative-sustainable-112400109</link>
<guid isPermaLink="true">https://6ix.com/company/basf-se/news/ourplasticsjourney-basf-showcases-innovative-sustainable-112400109</guid>
<pubDate>Mon, 19 Jan 2026 11:24:00 GMT</pubDate>
<description>BASF announced today its participation in PlastIndia 2026, scheduled to take place from February 5 to 10, 2026 in New Delhi, India. A broad portfolio of sustainable performance materials, innovative applications, and advanced product solutions will be presented. By showcasing exhibits across the 'Make', 'Use' and 'Recycle' phases, BASF underscores its commitment to driving sustainability, enabling circularity, and delivering high-performance solutions across many industries including automotive,</description>
</item>
<item>
<title>Bayer Ag Na: Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-welcomes-u-supreme-court-203000755</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-welcomes-u-supreme-court-203000755</guid>
<pubDate>Fri, 16 Jan 2026 20:30:00 GMT</pubDate>
<description>LEVERKUSEN, January 16, 2026--The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in authority among federal circuit courts on the application of federal preemption, a cross-cutting issue in the Roundup™ litigation. The company expects a decision on the merits during the Court’s 2026 session, which ends in June.</description>
</item>
<item>
<title>Bayer Ag Na: Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease</title>
<link>https://6ix.com/company/bayer-ag-na/news/belief-biomed-congratulates-partner-askbio-on-ind-acceptance-by-fda-for-investigational-gene-therapy-for-late-onset-pompe-disease</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/belief-biomed-congratulates-partner-askbio-on-ind-acceptance-by-fda-for-investigational-gene-therapy-for-late-onset-pompe-disease</guid>
<pubDate>Thu, 15 Jan 2026 04:11:00 GMT</pubDate>
<description>AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for AB-1009, an investigational adeno-associated virus (AAV) gene therapy being developed for the treatment of late-onset Pompe disease. With this announcement, the AB-1009 program advances to Phase 1/2, and AskBio initiates a clinical trial in the</description>
</item>
<item>
<title>Bayer Ag Na: Bayer Accelerates Pharma Growth on High-Value Portfolio</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-accelerates-pharma-growth-high-191500661</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-accelerates-pharma-growth-high-191500661</guid>
<pubDate>Tue, 13 Jan 2026 19:15:00 GMT</pubDate>
<description>SAN FRANCISCO, January 13, 2026--On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026.</description>
</item>
<item>
<title>Bayer Ag Na: Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause</title>
<link>https://6ix.com/company/bayer-ag-na/news/actress-and-menopause-advocate-gabrielle-union-wade-partners-with-bayer-in-the-lynkuetr-elinzanetant-life-doesnt-stop-for-a-hot-flash-campaign-for-moderate-to-severe-hot-flashes-due-to-menopause</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/actress-and-menopause-advocate-gabrielle-union-wade-partners-with-bayer-in-the-lynkuetr-elinzanetant-life-doesnt-stop-for-a-hot-flash-campaign-for-moderate-to-severe-hot-flashes-due-to-menopause</guid>
<pubDate>Tue, 13 Jan 2026 14:00:00 GMT</pubDate>
<description>WHIPPANY, N.J., January 13, 2026--Bayer today announced it has partnered with actress and menopause advocate Gabrielle Union-Wade on the ‘Life Doesn’t Stop for a Hot Flash’ campaign, which speaks to women with moderate to severe hot flashes due to menopause. The campaign encourages women to have an open and honest conversation with their healthcare provider about their hot flash experiences and learn about treatment options, including Lynkuet® (elinzanetant) 60mg capsules, a hormone-free prescri</description>
</item>
<item>
<title>Bayer Ag Na: Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-to-expand-into-molecular-imaging-with-acquisition-of-innovative-pan-amyloid-radiotracers-from-attralus</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-to-expand-into-molecular-imaging-with-acquisition-of-innovative-pan-amyloid-radiotracers-from-attralus</guid>
<pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
<description>BERLIN & NAPLES, Fla., January 12, 2026--Bayer, a leading company in key areas of radiology and cardiology, and Attralus, Inc. (Attralus), a clinical stage biopharmaceutical company focused on developing medicines and diagnostics for systemic amyloidosis, today announced that the companies have entered into definitive agreements for Bayer to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m), two investigational molecular imaging agents for the diagnosis of cardiac a</description>
</item>
<item>
<title>Bayer Ag Na: Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-souffl-therapeutics-announce-strategic-073000695</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-souffl-therapeutics-announce-strategic-073000695</guid>
<pubDate>Thu, 08 Jan 2026 07:30:00 GMT</pubDate>
<description>BERLIN & BOSTON, January 08, 2026--Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration and global licensing agreement to advance a heart-targeted small interfering RNA (siRNA) therapy. The companies will collaborate to develop a siRNA-based treatment for a form of dilated cardiomyopathy, addressing a rare subset of heart disease.</description>
</item>
<item>
<title>Bayer Ag Na: Bayer and Cradle enter collaboration to enhance AI-enabled antibody discovery and optimization</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-and-cradle-enter-collaboration-to-enhance-ai-enabled-antibody-discovery-and-optimization</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-and-cradle-enter-collaboration-to-enhance-ai-enabled-antibody-discovery-and-optimization</guid>
<pubDate>Wed, 07 Jan 2026 12:00:00 GMT</pubDate>
<description>Bayer and Cradle today announced that they have entered a three-year strategic collaboration to deploy Cradle's scientific AI software platform for protein engineering. As part of the collaboration, Bayer will integrate the generative AI platform into existing R&D workflows to enhance lead generation and optimization across its therapeutic antibody pipeline.</description>
</item>
<item>
<title>Bayer Ag Na: Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-to-present-updates-on-pharma-growth-strategy-and-pipeline-advancements-at-jp-morgans-44th-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-to-present-updates-on-pharma-growth-strategy-and-pipeline-advancements-at-jp-morgans-44th-annual-healthcare-conference</guid>
<pubDate>Mon, 05 Jan 2026 17:54:00 GMT</pubDate>
<description>WHIPPANY, N.J., January 05, 2026--Bayer will participate in the 44th J.P. Morgan Healthcare Conference 2026 taking place from January 12–15, 2026 in San Francisco. Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer’s Pharmaceuticals Division, will present updates on the company’s pharmaceutical growth strategy and pipeline advancements across its portfolio.</description>
</item>
<item>
<title>Basf Se: ADAMA and BASF Agricultural Solutions Partner to Co-Develop Breakthrough Gilboa® Fungicide Technology</title>
<link>https://6ix.com/company/basf-se/news/adama-and-basf-agricultural-solutions-partner-to-co-develop-breakthrough-gilboar-fungicide-technology</link>
<guid isPermaLink="true">https://6ix.com/company/basf-se/news/adama-and-basf-agricultural-solutions-partner-to-co-develop-breakthrough-gilboar-fungicide-technology</guid>
<pubDate>Thu, 18 Dec 2025 09:36:00 GMT</pubDate>
<description>ADAMA Ltd. (SZSE: 000553), and BASF announced a strategic co-development and commercialization agreement centered on ADAMA's proprietary fungicide active ingredient, Gilboa® (flumetylsulforim). This partnership will accelerate the delivery of new, pioneering disease management solutions, helping farmers across Europe combat resistance and maintain healthy yields.</description>
</item>
<item>
<title>Bayer Ag Na: Introducing Sivanto Energy: Enhanced Flea Beetle Control</title>
<link>https://6ix.com/company/bayer-ag-na/news/introducing-sivanto-energy-enhanced-flea-beetle-control</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/introducing-sivanto-energy-enhanced-flea-beetle-control</guid>
<pubDate>Tue, 16 Dec 2025 15:00:00 GMT</pubDate>
<description>CALGARY, Alberta, December 16, 2025--Bayer Crop Science Canada is excited to announce the launch of Sivanto® Energy, a groundbreaking foliar insecticide designed to deliver swift, reliable pest control with extended protection. Formulated to deliver two highly effective modes of action, Sivanto Energy combines the strengths of deltamethrin and flupyradifurone to provide unparalleled control over flea beetle pressure in canola.</description>
</item>
<item>
<title>Bayer Ag Na: Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-starts-phase-iia-study-for-treatment-of-patients-with-alport-syndrome</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-starts-phase-iia-study-for-treatment-of-patients-with-alport-syndrome</guid>
<pubDate>Thu, 04 Dec 2025 07:30:00 GMT</pubDate>
<description>BERLIN, December 04, 2025--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, placebo-controlled, group-comparison trial (NCT07211685), with an extension phase, which will investiga</description>
</item>
<item>
<title>Bayer Ag Na: RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints</title>
<link>https://6ix.com/company/bayer-ag-na/news/rsna25-pediatric-study-for-bayers-investigational-mri-contrast-agent-gadoquatrane-meets-primary-and-secondary-endpoints</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/rsna25-pediatric-study-for-bayers-investigational-mri-contrast-agent-gadoquatrane-meets-primary-and-secondary-endpoints</guid>
<pubDate>Wed, 03 Dec 2025 18:00:00 GMT</pubDate>
<description>WHIPPANY, N.J., December 03, 2025--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic resonance imaging (MRI) at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a dose reductio</description>
</item>
<item>
<title>Bayer Ag Na: Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-starts-new-phase-iii-study-with-mirenar-for-the-treatment-of-nonatypical-endometrial-hyperplasia</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-starts-new-phase-iii-study-with-mirenar-for-the-treatment-of-nonatypical-endometrial-hyperplasia</guid>
<pubDate>Tue, 02 Dec 2025 13:05:00 GMT</pubDate>
<description>WHIPPANY, N.J., December 02, 2025--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women.</description>
</item>
<item>
<title>Bayer Ag Na: Bayer Crop Science Canada Launches EverGol Rise for Enhanced User Experience in Pulse Disease Control</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-crop-science-canada-launches-evergol-rise-for-enhanced-user-experience-in-pulse-disease-control</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-crop-science-canada-launches-evergol-rise-for-enhanced-user-experience-in-pulse-disease-control</guid>
<pubDate>Tue, 02 Dec 2025 11:00:00 GMT</pubDate>
<description>CALGARY, Alberta, December 02, 2025--Bayer Crop Science Canada announced the launch of EverGol® Rise, setting a new standard in pulse disease control. Combining four different active ingredients, EverGol Rise brings enhanced disease control to tough pathogens, like ascochyta, while also keeping the user ease of use top of mind.</description>
</item>
<item>
<title>Bayer Ag Na: Bayer Welcomes Solicitor General Support for U.S. Supreme Court Review</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-welcomes-solicitor-general-support-for-us-supreme-court-review</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-welcomes-solicitor-general-support-for-us-supreme-court-review</guid>
<pubDate>Tue, 02 Dec 2025 00:13:00 GMT</pubDate>
<description>LEVERKUSEN, Germany, December 02, 2025--Bayer is pleased the Solicitor General supports U. S. Supreme Court review of the petition for a writ of certiorari in the Durnell case and agrees with the company’s arguments on preemption. The company believes that the backing of the U.S. government will be important to the Court’s consideration of its petition. The split among federal circuit courts in the Roundup™ personal injury litigation, on the cross-cutting question of whether federal law preempts</description>
</item>
<item>
<title>Bayer Ag Na: Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayers-medradr-centargo-multi-patient-ct-injection-system-now-with-a-wider-range-of-compatible-ct-contrast-agents-and-presentations</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayers-medradr-centargo-multi-patient-ct-injection-system-now-with-a-wider-range-of-compatible-ct-contrast-agents-and-presentations</guid>
<pubDate>Mon, 01 Dec 2025 16:30:00 GMT</pubDate>
<description>WHIPPANY, N.J., December 01, 2025--Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast agent presentations to include single-dose vials in addition to the previously cleared Imaging Bulk Package (IBP) presentations for Ultravist® (iopromide), Isovue® (iopamidol), Optiray® (ioversol) and Omnipaque™ (iohexol). Additionally, Bayer announced the addition of Vis</description>
</item>
<item>
<title>Bayer Ag Na: Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayers-asundexian-met-primary-efficacy-and-safety-endpoints-in-landmark-phase-iii-oceanic-stroke-study-in-secondary-stroke-prevention</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayers-asundexian-met-primary-efficacy-and-safety-endpoints-in-landmark-phase-iii-oceanic-stroke-study-in-secondary-stroke-prevention</guid>
<pubDate>Sun, 23 Nov 2025 16:28:00 GMT</pubDate>
<description>BERLIN, November 23, 2025--Bayer today announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. The study met its primary efficacy and safety endpoints. Asundexian 50 mg once daily significantly reduced the risk of ischemic stroke compared to placebo, both in combination with antiplatelet therapy, in patients after a non-cardioembolic ischemic stroke or high-risk ischemic attack. There was no increase</description>
</item>
<item>
<title>Bayer Ag Na: TetraScience and Bayer Expand Partnership to Advance Scientific Data Management</title>
<link>https://6ix.com/company/bayer-ag-na/news/tetrascience-and-bayer-expand-partnership-to-advance-scientific-data-management</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/tetrascience-and-bayer-expand-partnership-to-advance-scientific-data-management</guid>
<pubDate>Thu, 20 Nov 2025 11:00:00 GMT</pubDate>
<description>TetraScience, the Scientific Data and AI Company, announced that Bayer AG will expand its deployment of TetraScience's Scientific Data Foundry across its pharmaceutical and crop science R&D operations.</description>
</item>
<item>
<title>E.on Se: FPT and E.ON Extend Partnership to Drive AI-Powered Energy Management Innovation</title>
<link>https://6ix.com/company/eon-se/news/fpt-and-eon-extend-partnership-to-drive-ai-powered-energy-management-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/eon-se/news/fpt-and-eon-extend-partnership-to-drive-ai-powered-energy-management-innovation</guid>
<pubDate>Tue, 11 Nov 2025 01:00:00 GMT</pubDate>
<description>HANOI, Vietnam, November 11, 2025--Global technology and IT services provider FPT and E.ON Optimum, the digital solutions arm of E.ON UK, under E.ON Group, announced a new agreement to extend their collaboration in digital energy management. The signing marks the next phase of a partnership established in 2022, reaffirming both corporations’ shared vision of harnessing technology to accelerate innovation and sustainability in the energy sector.</description>
</item>
<item>
<title>Bayer Ag Na: Bayer Launches "Science Delivers" Campaign Celebrating the Transformative Power of Science</title>
<link>https://6ix.com/company/bayer-ag-na/news/bayer-launches-science-delivers-campaign-celebrating-the-transformative-power-of-science</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/bayer-launches-science-delivers-campaign-celebrating-the-transformative-power-of-science</guid>
<pubDate>Mon, 10 Nov 2025 12:01:00 GMT</pubDate>
<description>ST. LOUIS, November 10, 2025--Today, on World Science Day, Bayer is proud to launch its "Science Delivers" campaign, a nationwide initiative celebrating how science delivers answers, hope, and progress for all Americans—every day, in the moments that matter most.</description>
</item>
<item>
<title>Bayer Ag Na: Dr. Judith Hartmann to Become New Chief Financial Officer of Bayer AG</title>
<link>https://6ix.com/company/bayer-ag-na/news/dr-judith-hartmann-to-become-new-chief-financial-officer-of-bayer-ag</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/dr-judith-hartmann-to-become-new-chief-financial-officer-of-bayer-ag</guid>
<pubDate>Thu, 06 Nov 2025 16:44:00 GMT</pubDate>
<description>LEVERKUSEN, Germany, November 06, 2025--The Supervisory Board of Bayer AG has appointed Dr. Judith Hartmann to the company’s Board of Management, effective March 1, 2026. She will succeed Wolfgang Nickl as the company’s Chief Financial Officer (CFO) on June 1, 2026, following his planned retirement at the end of May 2026. Dr. Hartmann is currently an Operating Partner at Sandbrook Capital, a private investment firm focused on building leading climate infrastructure companies. Previously, she ser</description>
</item>
<item>
<title>Bayer Ag Na: KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease</title>
<link>https://6ix.com/company/bayer-ag-na/news/kerendiar-finerenone-meets-primary-endpoint-in-phase-iii-clinical-trial-for-adults-with-type-1-diabetes-and-chronic-kidney-disease</link>
<guid isPermaLink="true">https://6ix.com/company/bayer-ag-na/news/kerendiar-finerenone-meets-primary-endpoint-in-phase-iii-clinical-trial-for-adults-with-type-1-diabetes-and-chronic-kidney-disease</guid>
<pubDate>Thu, 06 Nov 2025 14:00:00 GMT</pubDate>
<description>WHIPPANY, N.J., November 06, 2025--Bayer today announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA® (finerenone) significantly reduced urine albumin-to-creatinine ratio (UACR) from baseline over six months by 25% compared to placebo in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) who were receiving standard of care (95% CI=0.75 [0.65; 0.87]; p=0.0001).1 These late-breaking data were presented today at the opening plenary sess</description>
</item>
</channel>
</rss>